Standard BioTools Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Standard BioTools Inc. specializes in the development and commercialization of advanced genomic and proteomic technologies designed to accelerate biological and therapeutic research. Its core product offerings include the SomaScan™ Select 3.7K Assay, which covers approximately 70% of FDA standard clinical biomarkers for comprehensive protein analysis; Single SOMAmer™ Reagents for precision antibody profiling; and the CyTOF™ XT PRO system, a next-generation platform that enables high-parameter immune profiling with up to 4x faster throughput to support clinical trial efficiency. Additionally, the company offers consumables, instruments, and services tailored to translational and clinical research in oncology, cardiometabolic disorders, immunology, and other therapeutic areas across human and non-human sample types. In recent strategic developments, Standard BioTools executed a significant restructuring plan in 2025 aimed at delivering over $40 million in annualized cost savings and improving operational efficiency, including a workforce reduction of approximately 20% globally and consolidating research and development operations into its Singapore facility. The company announced the strategic sale of its SomaLogic business segment to Illumina for up to $425 million, positioning Illumina to lead growth in high-plex proteomics while Standard BioTools retains rights to certain reagent commercializations and refocuses on core technologies. This transaction simplifies its operational structure and provides a substantial cash influx expected to fuel future inorganic growth strategies via disciplined mergers and acquisitions. Founded in 1999 and headquartered in Boston, Massachusetts, Standard BioTools serves global markets with its innovative solutions across pharmaceutical, bioprocessing, and clinical research sectors. It maintains strategic collaborations with prominent research institutions such as the California Institute of Technology and Harvard University, enhancing its research and development capabilities. The company emphasizes a portfolio that integrates hardware, software, and services through its proprietary Standard BioTools Business System (SBS), aiming to deliver reproducible, sensitive, and comprehensive molecular profiling tools to its customers worldwide. Standard BioTools' offerings extend beyond instrument sales to include CAP/CLIA-accredited laboratory services based in Boulder, Colorado, which provide SomaScan assay services, enhancing its position in proteomic analysis. The CyTOF XT PRO system's compliance with clinical trial regulation (21 CFR Part 11) further supports its adoption in regulated environments, highlighting its focus on clinical and translational research applications. The company projects fiscal year 2025 revenues between $165 million and $175 million, reflecting its targeted growth amid ongoing business transformation and market expansion efforts. Overall, Standard BioTools positions itself as a leader in precision genomic and proteomic solutions, strategically aligning its innovation pipeline, operational efficiencies, and market partnerships to capitalize on the evolving life sciences tools sector. Its recent strategic sale, product launches, operational consolidation, and focus on clinical research markets underscore its commitment to driving scientific discovery and therapeutic development globally.
Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.
Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion
Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global
Fluidigm Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution
Fluidigm Adjourns Special Meeting of Stockholders Until April 1, 2022
Fluidigm Urges Stockholders to Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion TODAY
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Fluidigm Stockholders Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion
Fluidigm Announces Fourth Quarter and Full Year 2021 Financial Results
Fluidigm Files Preliminary Proxy Statement in Connection with Proposed Strategic Capital Infusion from Casdin Capital and Viking Global Investors
Fluidigm Corporation: Investment Opportunity
Casdin Capital, Viking Global Investors Inject $250M In Fluidigm
Fluidigm Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and Rebranding to Standard BioTools Inc.
Fluidigm Shares Gain As Preliminary Q4, FY21 Sales Exceed Expectations
Fluidigm Confirms Advanta Dx SARS-CoV-2 RT-PCR Assay on the Company's Biomark Platform Detects Omicron Variant of COVID-19
Fluidigm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
Hot Penny Stocks To Buy Now? 4 To Add To Your List Today
Biomark X Offers Industry-Leading Advantages in Speed, Throughput, Flexibility and Cost
Fluidigm Q3 Sales Trail Estimates; Cuts Annual Guidance As COVID-19 Sales Retreat
Fluidigm Corporation (FLDM) CEO Chris Linthwaite on Q3 2021 Results - Earnings Call Transcript
Fluidigm Announces Third Quarter 2021 Financial Results